Palvella Therapeutics, Inc.
NCM: PVLALive Quote
📈 ZcoreAI Score
Our AI model analyzes Palvella Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PVLA Z-Score →About Palvella Therapeutics, Inc.
Healthcare
Biotechnology
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
📊 Fundamental Analysis
Palvella Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -92.1%, which indicates that capital utilization is currently under pressure.
At a current price of $127.12, PVLA currently trades near the top of its 52-week range (82%) (Range: $20.20 - $151.18).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.82B
Trailing P/E
--
Forward P/E
-19.32
Beta (5Y)
--
52W High
$151.18
52W Low
$20.20
Avg Volume
321K
Day High
Day Low